Amarin Corp Plc (AMRN)

[sts66]

Not such good news after all - and if the market and HF's know what this Suntrust guy does, no wonder this news barely moved the needle on the pps - with new trials needed, BB's "20 day review" is nowhere close to accurate, except maybe after NDA submission with the new data.

High teens for max royalties is a HORRIBLE deal - they better make up for that with those sales milestones, else they're damn near giving it away. Yeah, I know the Kowa deal is similar, but this is not even close to the same situation!

Eddingpharm will pay escalating royalties on net Vascepa sales in the low to high teens range. Given new clinical trials will be required & subject to regulatory review by the Chinese SFDA, our model assumes AMRN starts receiving royalties in 2019.